Cancerous leptomeningitis and familial congenital hypopituitarism

详细信息    查看全文

• 作者：S. Vujovic ; S. Vujosevic ; S. Kavaric ; J. Sopta ; M. Ivovic ; A. Saveanu ; T. Brue…
• 关键词：IGF ; I ; GH ; Cancer ; Familial congenital hypopituitarism
• 刊名：Endocrine
• 出版年：2016
• 出版时间：May 2016
• 年：2016
• 卷：52
• 期：2
• 页码：231-235
• 全文大小：1,308 KB
• 参考文献：1.M.N. Pollak, E.S. Schernhammer, S.E. Hankinson, Insulin-like growth factors and neoplasia. Nat. Rev. Cancer 4(7), 505–518 (2004)CrossRef PubMed
  2.A.G. Renehan, M. Zwahlen, C. Minder, S.T. Odwyer, S. Shalet, M. Egger, Insulin-like growth factor (IGF)-I, IGF binding protein 3 and cancer risk: systematic review and meta-regression analysis. Lancet 24;363(9418), 1346–1353 (2004)CrossRef
  3.W.E. Sonntag, C.S. Carter, Y. Ikeno, K. Ekenstedt, C.S. Carlson, R.F. Loeser, S. Chakrabarty, S. Lee, C. Bennett, R. Ingram, T. Moore, M. Ramsey, Adult-onset growth hormone and insulin-like growth factor I deficiency reduces neoplastic disease, modifies age-related pathology, and increases life span. Endocrinology 146, 2920–2932 (2005)CrossRef PubMed
  4.R. Steuerman, O. Shevah, Z. Laron, Congenital IGF1 deficiency tends to confer protection against post-natal development of malignancies. Eur. J. Endocrinol. 164(4), 485–489 (2011)CrossRef PubMed
  5.J. Guevara-Aguirre, P. Balasubramanian, M. Guevara-Aguirre, M. Wei, F. Madia, C.W. Cheng, D. Hwang, A. Martin-Montalvo, J. Saavedra, S. Ingles, C.R. De, P. Cohen, V.D. Longo, Growth hormone receptor deficiency is associated with a major reduction in pro-aging signaling, cancer, and diabetes in humans. Sci. Transl. Med. 3(70), 70ra13 (2011). doi:10.​1126/​scitranslmed.​3001845 PubMed PubMedCentral
  6.M.W. Sornson, W. Wu, J.S. Dasen, S.E. Flynn, D.J. Norman, S.M. O’Connell, I. Gukovsky, C. Carrie`re, A.K. Ryan, A.P. Miller, L. Zuo, A.S. Gleiberman, B. Andersen, W.G. Beamer, M.G. Rosenfeld, Pituitary lineage determination by the Prophet of Pit-1 homeodomain factor defective in Ames dwarfism. Nature 384, 327–333 (1996)CrossRef PubMed
  7.W. Wu, J.P. Cogan, R.W. Pfaffle, J.S. Dasen, H. Frisch, S.M. OConnell, S.E. Flynn, M.R. Brown, P.E. Mullis, J.S. Parks, J.A. Phillips, M.G. Rosenfeld, Mutation in PROP1 cause familial combined pituitary hormone deficiency. Nat. Genet. 18, 147–149 (1998)CrossRef PubMed
  8.M.T. Dattani, I.C. Robinson, The molecular basis for developmental disorders of the pituitary gland in man. Clin. Genet. 57, 337–346 (2000)CrossRef PubMed
  9.A.L. Rosenbloom, A.S. Almonte, M.R. Brown, D.A. Fisher, L. Baumbach, J.S. Parks, Clinical and biochemical phenotype of familial anterior hypopituitarism from mutation of the PROP1 gene. J. Clin. Endocrinol. Metab. 84, 50–57 (1999)PubMed
  10.S. Mody, M. Brown, J.S. Parks, The spectrum of hypopituitarism caused by PROP1 mutations. Best Pract. Res. Clin. Endocrinol. Metab. 16, 421–431 (2002)CrossRef PubMed
  11.M. Doknic, S. Pekic, M. Djurovic, V. Zivkovic, V. Popovic, Multiple pituitary hormone deficiency (MPHD) associated with normal height, absent puberty and obesity. Pediatr. Endocrinol. Rev. 1, 32–33 (2004)
  12.M.H. Aguiar-Oliveira, F.T. Oliveira, R.M. Pereira, C.R. Oliveira, A. Blackford, E.H. Valenca, E.G. Santos, M.B. Gois-Junior, R.A. Meneguz-Moreno, V.P. Araujo, L.A. Oliveira-Neto, R.P. Almeida, M.A. Santos, N.T. Farias, D.C. Silveira, G.W. Cabral, F.R. Calazans, J.D. Seabra, T.F. Lopes, E.O. Rodrigues, L.A. Porto, I.P. Oliveira, E.V. Melo, M. Martari, R. Salvatori, Longevity in untreated congenital growth hormone deficiency due to a homozygous mutation in the GHRH receptor gene. J. Clin. Endocrinol. Metab. 95, 714–721 (2010)CrossRef PubMed PubMedCentral
  13.V. Anisimov, A. Bartke, The key role of growth hormone-insulin-IGF1 signaling in aging and cancer. Crit. Rev. Oncol. Hematol. 87, 201–223 (2013)CrossRef PubMed PubMedCentral
  14.R.G. Rosenfeld, P. Cohen, L.L. Robison, B.B. Bercu, P. Clayton, A.R. Hoffman, S. Radovick, P. Saenger, M.O. Savage, J.M. Wit, Long-term surveillance of growth hormone therapy. J. Clin. Endocrinol. Metab. 97, 68–72 (2012)CrossRef PubMed
  15.S. Pekic, V. Popovic, GH therapy and cancer risk in hypopituitarism: what we know from human studies. Eur. J. Endocrinol. 169(5), R89–R97 (2013). doi:10.​1530/​EJE-13-0389 CrossRef PubMed
  16.J. Ferlay, I. Soerjomataram, R. Dikshit, S. Eser, C. Mathers, M. Rebelo, D.M. Parkin, D. Forman, F. Bray, Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int. J. Cancer Mar. 1:136(5), E359–E386 (2015)CrossRef
  17.E. Miller, I. Dy, T. Herzog, Leptomeningeal carcinomatosis from ovarian cancer. Med. Oncol. 29, 2010–2015 (2012)CrossRef PubMed
  18.D.A. Bell, Origins and molecular pathology of ovarian cancer. Mod. Pathol. 18(2), S19–S32 (2005)CrossRef PubMed
  19.C.L. Pearce, J. Doherty, D. Van Den Berg et al., Genetic variation in insulin-like growth factor 2 maz play a role in ovarian cancer risk. Hum. Mol. Genet. 20(11), 2263–2272 (2011)CrossRef PubMed PubMedCentral
  20.J. Ose, R.T. Fortner, H. Schock et al., Insulin-like growth factor I and risk of epithelial invasive ovarian cancer by tumour characteristics: results from the EPIC cohort. Br. J. Cancer 112(1), 162–166 (2014). doi:10.​1038/​bjc.​2014.​566 CrossRef PubMed PubMedCentral
  21.Q. Wang, C. Bian, H. Peng, X. Zhao, Association of circulating insulin-like growth factor 1 and insulin-like growth factor binding protein 3 with the risk of ovarian cancer: a systematic review and meta-analysis. Mol. Clin. Oncol. 3, 623–628 (2015)PubMed PubMedCentral
  22.C. Frank, M. Fallah, J. Sundquist, A. Hemminki, K. Hemminki, Population landscape of familial cancer. Sci. Rep. 5, 12891 (2015). doi:10.​1038/​srep12891 CrossRef PubMed PubMedCentral
  
• 作者单位：S. Vujovic (1)
  S. Vujosevic (2)
  S. Kavaric (2)
  J. Sopta (3)
  M. Ivovic (1)
  A. Saveanu (4) (5)
  T. Brue (4) (5)
  M. Korbonits (6)
  V. Popovic (1)
  
  1. Clinic of Endocrinology, Clinical Center Serbia and Medical Faculty, University of Belgrade, Dr Subotic Str 13, 11000, Belgrade, Serbia
  2. Clinical Center of Montenegro and Faculty of Medicine, University of Montenegro, Podgorica, Montenegro
  3. Institute of Pathology, Medical Faculty, University of Belgrade, Belgrade, Serbia
  4. Aix-Marseille Université, CNRS, CRN2M UMR 7286, 13344, Marseille Cedex 15, France
  5. APHM, Hôpital Conception, Service d’Endocrinologie, Diabète et Maladies Métaboliques, Centre de Référence des Maladies Rares d’Origine Hypophysaire DEFHY, and Laboratoire de Biologie Moleculaire, GeOneE (Genetique Oncologique et Endocrinienne), 13385, Marseille Cedex 15, France
  6. Department of Endocrinology, William Harvey Research Institute, Barts and the London School of Medicine, Queen Mary University of London, Charterhouse Square, London, EC1M 6BQ, UK
  
• 刊物主题：Endocrinology; Diabetes; Internal Medicine; Science, general;
• 出版者：Springer US
• ISSN：1559-0100

文摘

People are at higher risk of cancer as they get older or have a strong family history of cancer. The potential influence of environmental and behavioral factors remains poorly understood. Earlier population and case control studies reported that upper quartile of circulating IGF-I is associated with a higher risk of developing cancer suggesting possible involvement of the growth hormone (GH)/IGF system in initiation or progression of cancer. Since GH therapy increases IGF-1 levels, there have been concerns that GH therapy in hypopituitarism might increase the risk of cancer. We report a 42-year-old female patient who presented with subacute onset of symptoms of meningitis and with the absence of fever which resulted in death 70 days after the onset of symptoms. The patient together with her younger brother was diagnosed at the age of 5 years with familial congenital hypopituitarism, due to homozygous mutation c.150delA in PROP1 gene. Due to evolving hypopituitarism, she was replaced with thyroxine (from age 5), hydrocortisone (from age 13), GH (from age 13 until 17), and sex steroids in adolescence and adulthood. Her consanguineous family has a prominent history of malignant diseases. Six close relatives had malignant disease including her late maternal aunt with breast cancer. BRCA 1 and BRCA 2 mutational analysis in the patient’s mother was negative. Histology after autopsy disclosed advanced ovarian cancer with multiple metastases to the brain, leptomeninges, lungs, heart, and adrenals. Low circulating IGF-1 did not seem to protect this patient from cancer initiation and progression in the context of strong family history of malignancies.